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OBJECTIVES: Chronic kidney disease (CKD) has been a leading public health 
problem. The purpose of this study was to evaluate direct and indirect costs of 
patients with chronic kidney disease in China, producing an average cost per 
patient per year and the overall economic burden of the whole chronic kidney 
disease population in China. METHODS: A cost-of-illness analyses was 
performed. Prevalence data on chronic kidney disease for the Chinese population 
was collected from literatures. An observational retrospective study was 
conducted to collect the economic data. We recruited 401 patients diagnosed 
with chronic kidney disease with 281 patients in 3-4 stage of CKD and 120 
patients in the 5th stage of CKD in Beijing, Shanghai, Guangzhou and Chengdu 
between November 2012 and December2012. Patients or their carers were 
interviewed about resource utilization and absenteeism from work in the past 
year.All costs referred to 2012. RESULTS: Among 401 patients with CKD, 56.4% 
were male and the mean age was 58.0±15.7 years. 94.3% patients in 3-4 stage of 
CKD and 98.2% patients in the 5th stage of CKD have at least one kind of health 
insurance. From the societal perspective, total costs per patient over 1 year 
amounted to Chinese Yuan (CNY) 34205 (median: CNY24246, IQR: CNY16271 -
CNY 34958) for patients in 3-4 stage of CKD with direct cost accounting for 97.7% 
of the total, and Chinese Yuan (CNY) 128231 (median: CNY 103450, IQR: CNY 
85351 -CNY 159726) for patients in 5th stage of CKD with direct cost accounting 
for 82.3% of the total. For the direct costs, the outpatient and inpatients visit 
costs were CNY100374.6 and indirect costs were CNY22687.4. CONCLUSIONS: 
The economic burden of chronic kidney disease in China is considerable, 
especially for patients in 1-4 stage of CKD. The primary burden on patients was 
due to direct medical cost.  
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OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD) is a 
progressive disease characterized by cyst growth and loss of kidney function. We 
evaluated medical resource use (MRU) and costs associated with ADPKD by 
disease stage. METHODS: This retrospective cohort study was based on US 
Medicare data. ADPKD patients were identified by a diagnosis of ADPKD; and 
further classified by disease stage using codes for chronic kidney disease (CKD) 
stage, dialysis use, or previous kidney transplant. Six-month ADPKD MRU and 
costs were assessed by disease stage and compared to those of a sex- and age-
matched cohort of patients without ADPKD (without matching for CKD stage). 
RESULTS: A total of 1246 ADPKD patients were analyzed (25, 56, 174, 153, 113 in 
Stage 1 - 5 CKD, respectively; 603, 293 in the dialysis and post-transplant disease 
stages). Average age ranged from 58-72 across all disease stages. The proportion 
of patients with >= 1 hospitalization in six months ranged from 21% in CKD 
Stage 2 to 44% in CKD Stage 5; 74% of dialysis and 51% of post-transplant 
patients were hospitalized. Most patients in each subgroup had >= 1 medical 
outpatient visit within six months of disease. Across all disease stages, total six-
month per-patient costs were higher among ADPKD patients compared to age 
and gender matched controls (CKD1: $12,190 vs. $2,845; CKD2 $6,978 vs. $3,567; 
CKD3 $10,008 vs. $3,768; CKD 4: $14,320 vs. $3,660; CKD5: $14,466 vs. $3,450; 
dialysis: $43,452 vs. $3,417; post-transplant: $17,957 vs. $3,846; P < 0.05 for all 
comparisons). CONCLUSIONS: Even at early stage CKD, ADPKD imposes a sizable 
and significant economic burden on the Medicare system, relative to the general 
population. Costs increase in magnitude with declining kidney function. 
Potential cost offsets may be achieved by early intervention with treatments that 
have a positive impact on ADPKD disease progression.  
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OBJECTIVES: Acute kidney injury (AKI) is a serious complication of cardiac 
surgery and is consistently associated with poor outcomes. Nevertheless, due to 
differences in surgical procedures and approaches to identifying AKI, the costs 
and outcomes vary across studies. This study aimed to determine the length of 
stay, costs, and mortality attributable to AKI in high risk cardiac surgery (HRCS) 
patients from a large database over 10 years. METHODS: Using the 
comprehensive administrative hospital database from Premier, which includes 
20% of all hospitalizations in the US, adults undergoing coronary artery bypass 
grafting (CABG), cardiac valve replacement or aortic repair surgery between 2000-
2011 were identified. AKI was identified perioperatively from ICD-9 diagnosis 
codes. Cost and LOS were also determined using claim and discharge data. 
Patients having a post-operative AKI event coded were compared to matched 
controls based upon age, HRCS type, surgery year, provider facility, and 
admission type. RESULTS: Of the 142,550 HRCS admissions meeting our criteria, 
25,849 (18.1%) had AKI. Matching was successful in 83.2% of the cases, leading to 
21,514 cases and 21,514 controls. Sixty-six percent of the cases were classified as 
high risk CABG, 7.9% as valve replacement and 26.0% as aortic repair surgery. Of 
the cases, 19.6% versus 3.3% of the controls (p<.001) died during hospitalization. 
The mean overall cost of post-operative care for patients with AKI was $67,089 
(95% CI: 66,166 - 68,012) versus $39,657 (95% CI: 39,274 - 40,040) for controls 
(p<0.001). Median cost for cases was $49,372 versus $34,277 for controls (p<0.001). 
Mean length of ICU/total postoperative lengths of stay for admissions were 
5.76/16.83 days for patients with AKI compared with 2.14/ 8.67 days for controls 
(p<0.001/p<0.001). CONCLUSIONS: AKI is associated with significantly increases 
in mortality, LOS, and costs across the post-operative HRCS patients.  
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OBJECTIVES: To understand the trends in rate and cost of hospitalizations due to 
Chronic Kidney Disease (CKD) in the U.S. METHODS: We analyzed the last five 
years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal 
Disease (ESRD). The annual number of hospitalizations for specific diagnosis was 
obtained from AHRQ's National In-patient Sample (NIS) databases of 2005-2009. 
Data was also analyzed for length of stay (LOS), charges and cost of 
hospitalization. RESULTS: During the last five years the number of 
hospitalizations with diagnosis of CKD and ESRD has increased 4.1 and 4.6 fold, 
respectively. In 2009, an estimated 1,634,422 and 931,641 hospitalizations were 
with diagnosis of CKD and ESRD respectively. The mean LOS for patients with 
CKD increased from 4.9 to 5.5 days between2005-2009. The mean LOS for 
patients with ESRD has remained steady at ~6 days between 2005-2009. The cost 
of hospitalization with diagnosis of CKD has increased 31% between 2005-2009. 
The cost of hospitalization with diagnosis of ESRD has increased 21% between 
2005-2009. In 2009, the mean cost of hospitalization for patients with CKD and 
ESRD was$11,209 and $21,358, respectively. CONCLUSIONS: Hospitalizations due 
to CKD and ESRD have significantly increased during the last five years. There is 
a need for prevention, treatment, and disease management programs to lower 
the medical and socioeconomic burden of this disease.  
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OBJECTIVES: this study is a cost-effectiveness analysis of immunosuppressive 
maintenance therapy after renal transplantation in Brazil. The aimed of  
this study was re-evaluating a possible impact on clinical decisions because  
of the new policy of pricing and access of tacrolimus due to the loss of  
patent. METHODS: a hypothetical cohort of 20 years to adult renal transplant 
patients in maintenance therapy was constructed using the Markov model.  
All regimens tested, as follows, contains prednisone: cyclosporine+azathioprine, 
cyclosporin+mycophenolate mofetil, cyclosporine+mycophenolate sodium, 
cyclosporine + sirolimus, everolimus + cyclosporine, tacrolimus + azathioprine, 
tacrolimus + mycophenolate mofetil, tacrolimus + mycophenolate sodium, 
sirolimus + tacrolimus, sirolimus + mycophenolate mofetil. The efficacy 
estimates were obtained from the literature. The average price of drugs was 
based on the price list of Brazilian Regulatory Pharmaceutical Market Chamber, 
relative to October 2012. The costs of the disease stage were taken from 
literature. The cost was expressed in dollars (U$) and these values were 
converted using the purchasing power parity factor of 1.81. The effectiveness 
was measured in life years gained (LY) and adopted the public health system 
perspective. Sensitivity analyzes were performed. RESULTS: even with a 
reduction equivalent to 53.5% of the price of tacrolimus, and considering the 
analysis with 5% discount in cost and effect established in the Brazilian 
guidelines for assessing technology, all the schemes were dominated by 
cyclosporine + azathioprine + prednisone. In other analyzes, the scheme 
tacrolimus + azathioprine + prednisone was not dominated, but the Incremental 
Cost-Effectiveness Ratio of these two schemes was U$ 86,592.30/LY in the 
analysis without discount. This ratio is higher than the Brazilian reference value 
of three times GDP per capita, used for embedding. No qualitative change was 
demonstrated by sensitivity analysis and the likelihood of the scheme 
cyclosporine + azathioprine + prednisone be the most cost-effective is greater 
than 85%. CONCLUSIONS: In Brazilian context, cyclosporine remains more cost-
effective for maintenance treatment of kidney transplant, even after the price of 
tacrolimus having reduced.  
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OBJECTIVES: To conduct cost-effectiveness and cost-utility analyses of a model 
of treatment for urge incontinence in community-dwelling older adults. 
METHODS: A decision-analytic, cost effectiveness/utility model was constructed 
in TreeAge pro 2009 that examined three treatment pathways starting 
withlimited behavioral therapy (LBT), full behavioral therapy (FBT) or drug 
(DRUG) treatment with each followed by possible crossover to or adding  
an alternative therapy based on treatment results. RESULTS: All strategies 
compared to no treatment prevented incontinence episodes and generated 
additional QALYs. Compared to no treatment, the costs per QALY gained ranged 
from $2850 to $7276. At baseline values, LBT was the least costly, but produced 
the least benefit. DRUG was the most expensive and produced less benefit  
than FBT. Only small changes in withdrawal rates and baseline effectiveness 
